Grisanti Capital Management LLC Sells 3,416 Shares of CME Group Inc (CME)

Grisanti Capital Management LLC reduced its stake in CME Group Inc (NASDAQ:CME) by 15.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,716 shares of the financial services provider’s stock after selling 3,416 shares during the period. CME Group makes up about 1.6% of Grisanti Capital Management LLC’s investment portfolio, making the stock its 24th biggest holding. Grisanti Capital Management LLC’s holdings in CME Group were worth $3,186,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CME. DnB Asset Management AS boosted its position in CME Group by 8.4% in the 2nd quarter. DnB Asset Management AS now owns 41,415 shares of the financial services provider’s stock valued at $6,789,000 after buying an additional 3,200 shares during the last quarter. IFM Investors Pty Ltd boosted its position in CME Group by 43.5% in the 2nd quarter. IFM Investors Pty Ltd now owns 15,288 shares of the financial services provider’s stock valued at $2,506,000 after buying an additional 4,635 shares during the last quarter. YHB Investment Advisors Inc. boosted its position in CME Group by 3.0% in the 2nd quarter. YHB Investment Advisors Inc. now owns 27,571 shares of the financial services provider’s stock valued at $4,519,000 after buying an additional 808 shares during the last quarter. CENTRAL TRUST Co boosted its position in CME Group by 42.0% in the 2nd quarter. CENTRAL TRUST Co now owns 9,898 shares of the financial services provider’s stock valued at $1,622,000 after buying an additional 2,927 shares during the last quarter. Finally, Cullinan Associates Inc. boosted its position in CME Group by 7.2% in the 2nd quarter. Cullinan Associates Inc. now owns 41,810 shares of the financial services provider’s stock valued at $6,853,000 after buying an additional 2,810 shares during the last quarter. Hedge funds and other institutional investors own 84.28% of the company’s stock.

In other CME Group news, CFO John W. Pietrowicz sold 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, October 11th. The shares were sold at an average price of $179.86, for a total value of $449,650.00. Following the sale, the chief financial officer now owns 32,720 shares in the company, valued at $5,885,019.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Jack J. Tobin sold 7,820 shares of the firm’s stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $174.87, for a total transaction of $1,367,483.40. Following the completion of the sale, the chief accounting officer now owns 17,534 shares in the company, valued at approximately $3,066,170.58. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,679 shares of company stock worth $3,109,034. 0.43% of the stock is owned by company insiders.

CME has been the subject of a number of analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a $190.00 price objective on shares of CME Group in a research report on Wednesday, September 5th. BidaskClub raised shares of CME Group from a “hold” rating to a “buy” rating in a research report on Monday, July 16th. Deutsche Bank reissued a “buy” rating and issued a $192.00 price objective (up from $185.00) on shares of CME Group in a research report on Thursday, October 11th. Bank of America reissued a “buy” rating and issued a $200.00 price objective on shares of CME Group in a research report on Monday. Finally, Zacks Investment Research raised shares of CME Group from a “sell” rating to a “hold” rating in a research report on Wednesday, October 3rd. Five research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $182.69.

Shares of CME stock opened at $185.50 on Tuesday. The company has a current ratio of 1.09, a quick ratio of 1.08 and a debt-to-equity ratio of 0.15. CME Group Inc has a one year low of $136.35 and a one year high of $186.76. The stock has a market cap of $62.42 billion, a PE ratio of 38.89, a P/E/G ratio of 3.47 and a beta of 0.49.

CME Group (NASDAQ:CME) last issued its quarterly earnings results on Thursday, October 25th. The financial services provider reported $1.45 EPS for the quarter, topping the consensus estimate of $1.42 by $0.03. CME Group had a net margin of 113.67% and a return on equity of 9.18%. The business had revenue of $904.20 million for the quarter, compared to analysts’ expectations of $910.50 million. As a group, analysts anticipate that CME Group Inc will post 6.63 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/11/06/grisanti-capital-management-llc-sells-3416-shares-of-cme-group-inc-cme.html.

CME Group Company Profile

CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural products, and metals.

Featured Article: Moving Average – How it Helps Investors in Stock Selection

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply